Annual Operating Expenses
$510.53 M
+$54.55 M+11.96%
December 31, 2023
Summary
- As of February 12, 2025, TVTX annual total operating expenses is $510.53 million, with the most recent change of +$54.55 million (+11.96%) on December 31, 2023.
- During the last 3 years, TVTX annual operating expenses has risen by +$242.96 million (+90.80%).
- TVTX annual operating expenses is now at all-time high.
Performance
TVTX Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Operating Expenses
$117.30 M
-$1.81 M-1.52%
September 30, 2024
Summary
- As of February 12, 2025, TVTX quarterly total operating expenses is $117.30 million, with the most recent change of -$1.81 million (-1.52%) on September 30, 2024.
- Over the past year, TVTX quarterly operating expenses has dropped by -$6.04 million (-4.89%).
- TVTX quarterly operating expenses is now -34.41% below its all-time high of $178.85 million, reached on March 31, 2024.
Performance
TVTX Quarterly Operating Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Operating Expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
TVTX Operating Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +12.0% | -4.9% |
| 3 y3 years | +90.8% | +1.9% |
| 5 y5 years | +124.5% | +1.9% |
TVTX Operating Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +41.7% | -34.4% | +64.1% |
| 5 y | 5-year | at high | +90.8% | -34.4% | +85.0% |
| alltime | all time | at high | >+9999.0% | -34.4% | >+9999.0% |
Travere Therapeutics Operating Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $117.30 M(-1.5%) |
| Jun 2024 | - | $119.11 M(-33.4%) |
| Mar 2024 | - | $178.85 M(+45.0%) |
| Dec 2023 | $510.53 M(+12.0%) | $123.33 M(-3.9%) |
| Sep 2023 | - | $128.39 M(-4.7%) |
| Jun 2023 | - | $134.69 M(+8.5%) |
| Mar 2023 | - | $124.11 M(+7.8%) |
| Dec 2022 | $455.99 M(+26.6%) | $115.17 M(+5.1%) |
| Sep 2022 | - | $109.56 M(-2.7%) |
| Jun 2022 | - | $112.66 M(+9.0%) |
| Mar 2022 | - | $103.40 M(+44.7%) |
| Dec 2021 | $360.21 M(+34.6%) | $71.47 M(-15.4%) |
| Sep 2021 | - | $84.47 M(-2.7%) |
| Jun 2021 | - | $86.77 M(+2.4%) |
| Mar 2021 | - | $84.72 M(+14.3%) |
| Dec 2020 | $267.57 M(-0.9%) | $74.12 M(+15.3%) |
| Sep 2020 | - | $64.30 M(-2.2%) |
| Jun 2020 | - | $65.76 M(+3.7%) |
| Mar 2020 | - | $63.39 M(-0.8%) |
| Dec 2019 | $269.91 M(+18.7%) | $63.90 M(+2.6%) |
| Sep 2019 | - | $62.30 M(-19.0%) |
| Jun 2019 | - | $76.90 M(+16.3%) |
| Mar 2019 | - | $66.11 M(+13.6%) |
| Dec 2018 | $227.41 M(+24.9%) | $58.19 M(-0.6%) |
| Sep 2018 | - | $58.55 M(-1.7%) |
| Jun 2018 | - | $59.56 M(+16.5%) |
| Mar 2018 | - | $51.10 M(+9.1%) |
| Dec 2017 | $182.13 M | $46.85 M(+5.4%) |
| Sep 2017 | - | $44.46 M(-8.0%) |
| Jun 2017 | - | $48.32 M(+9.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $43.98 M(-5.0%) |
| Dec 2016 | $167.97 M(+29.2%) | $46.29 M(-1.7%) |
| Sep 2016 | - | $47.09 M(+15.2%) |
| Jun 2016 | - | $40.88 M(+21.0%) |
| Mar 2016 | - | $33.80 M(-11.4%) |
| Dec 2015 | $129.97 M(+21.0%) | $38.14 M(+4.9%) |
| Sep 2015 | - | $36.37 M(+20.2%) |
| Jun 2015 | - | $30.25 M(+20.0%) |
| Mar 2015 | - | $25.20 M(-22.3%) |
| Dec 2014 | $107.44 M(+333.7%) | $32.44 M(+8.1%) |
| Sep 2014 | - | $30.02 M(+31.1%) |
| Jun 2014 | - | $22.89 M(+3.6%) |
| Mar 2014 | - | $22.09 M(+80.0%) |
| Dec 2013 | $24.77 M(-18.1%) | $12.27 M(+138.0%) |
| Sep 2013 | - | $5.15 M(+1.1%) |
| Jun 2013 | - | $5.10 M(+170.5%) |
| Mar 2013 | - | $1.89 M(>+9900.0%) |
| Dec 2012 | $30.26 M(>+9900.0%) | - |
| Nov 2012 | - | $3200.00(+6.7%) |
| Aug 2012 | - | $3000.00(0.0%) |
| May 2012 | - | $3000.00(-21.1%) |
| Feb 2012 | - | $3800.00(+26.7%) |
| Feb 2012 | $12.80 K(+0.8%) | - |
| Nov 2011 | - | $3000.00(0.0%) |
| Aug 2011 | - | $3000.00(0.0%) |
| May 2011 | - | $3000.00(-16.7%) |
| Feb 2011 | $12.70 K | $3600.00(+16.1%) |
| Nov 2010 | - | $3100.00(-53.0%) |
| Aug 2010 | - | $6600.00(0.0%) |
| May 2010 | - | $6600.00 |
FAQ
- What is Travere Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Travere Therapeutics?
- What is Travere Therapeutics annual operating expenses year-on-year change?
- What is Travere Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Travere Therapeutics?
- What is Travere Therapeutics quarterly operating expenses year-on-year change?
What is Travere Therapeutics annual total operating expenses?
The current annual operating expenses of TVTX is $510.53 M
What is the all time high annual operating expenses for Travere Therapeutics?
Travere Therapeutics all-time high annual total operating expenses is $510.53 M
What is Travere Therapeutics annual operating expenses year-on-year change?
Over the past year, TVTX annual total operating expenses has changed by +$54.55 M (+11.96%)
What is Travere Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of TVTX is $117.30 M
What is the all time high quarterly operating expenses for Travere Therapeutics?
Travere Therapeutics all-time high quarterly total operating expenses is $178.85 M
What is Travere Therapeutics quarterly operating expenses year-on-year change?
Over the past year, TVTX quarterly total operating expenses has changed by -$6.04 M (-4.89%)